



Amendments to the Claims:

Claims 1-57 (Cancelled)

Claim 58 (Currently Amended): The compound of claim 75, or a pharmaceutically acceptable salt thereof, said compound having the formula:




wherein R₁ is a cycloalkyl group of the formula, n being 1-2



CO_2H and R_1 can also optionally be substituted with at least one halo atom or at least one C_1 to C_3 alkyl group; R_2 , R_3 , R_6 , R_7 , R_8 , R_9 , or R_{11} are each independently H , OCH_3 , CH_3 or CH_2CH_3 ; R_4 is CN , CO_2H , CHO , CH_3 , CONH_2 , CHNH ; R_5 , R_{10} are OH ; or analogues differing from the corresponding "natural" compound in the oxidation state of one or more of the ketide units, with the proviso that said compounds are not borrelidin (**1**), 12-desnitrile-12-carboxyl borrelidin (**2**), 10-desmethyl borrelidin (**3**), 11-epiborrelidin (**4**) or C14,C15-*cis* borrelidin analogue (**5**) as shown in Figure 1.

Claim 59 (Currently Amended): The compound of claim 75, or a pharmaceutically acceptable salt thereof, said compound having the formula:

Formula 2



wherein R₂, R₃, R₆, R₇, R₈, R₉, or R₁₁ are each independently H, OCH₃, CH₃ or CH₂CH₃; R₄ is CN, CO₂H, CHO, CH₃, CONH₂, CHNH₂; R₅, R₁₀ are OH; ~~or analogues differing from the corresponding natural compound in the oxidation state of one or more of the ketide units (i.e. selection of alternatives from the group: CO, CH(OH), CH, and CH₂)~~, and R₁₂ and R₁₃ are independently H or a C1-C4 alkyl group which may be optionally substituted with OH, F, Cl, SH₂, with the proviso that R₁₂ and R₁₃ are not simultaneously H.

Claim 60 (Previously Presented): The compound or salt according to claim 75, wherein R₇, R₈ and R₉ of formulas 1 and 2 are all CH₃.

Claim 61 (Previously Presented): The compound or salt according to claim 75, wherein R₄ of formulas 1 and 2 is CH₃ or COOH.

Claim 62 (Previously Presented): The compound or salt according to claim 60 wherein R₄ of formulas 1 and 2 is CH₃ or COOH.

Claim 63 (Previously Presented): The compound or salt according to claim 75, wherein R₄ of formulas 1 and 2 is CN.

Claim 64 (Previously Presented): The compound or salt according to claim 60 wherein R₄ of formulas 1 and 2 is CN.

Claim 65 (Previously Presented): The compound or salt according to claim 58 wherein R₁ is cyclobutane-1'-carboxylate.

Claim 66 (Previously Presented): The compound or salt according to claim 60, wherein R₁ of formula 1 is cyclobutane-1'-carboxylate.

Claim 67 (Previously Presented): The compound or salt according to claim 66, wherein R₄ of formulas 1 and 2 is CH₃ or COOH.

Claim 68 (Previously Presented): The compound or salt according to claim 58, wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁ is cyclopentane-1'-carboxylate or cyclobutane-1'-carboxylate.

Claim 69 (Previously Presented): The compound or salt according to claim 59, wherein R₁₂ and R₁₃ are independently CH₃ or H.

Claim 70 (Previously Presented): The compound or salt according to claim 60, wherein R₁₂ and R₁₃ of formula 2 are independently CH₃ or H.

Claim 71 (Previously Presented): The compound or salt according to claim 70, wherein R₄ of formulas 1 and 2 is CH₃ or COOH.


Claim 72 (Previously Presented): The compound or salt according to claim 59 wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁₂ and R₁₃ are independently CH₃ or H.

Claim 73 (Previously Presented): The compound or salt

according to claim 59 wherein R₆, R₇, R₈ and R₉ are all CH₃, R₂ and R₁₁ are H, R₅ and R₁₀ are OH, R₄ is either CH₃, COOH or CN and R₁₂ and R₁₃ are both CH₃.


Claim 74 (Cancelled)

Claim 75 (Currently Amended): A compound, said compound being selected from the group consisting of formula 1,




, and pharmaceutically acceptable salts thereof, wherein

R₁ is a cycloalkyl group of the formula, n being 1- 2,



CO₂H and R₁ can also optionally be substituted with at least one halo atoms or at least one C₁ to C₃ alkyl groups; R₂, R₃, R₆, R₇, R₈, R₉, or R₁₁ are each independently H, OCH₃, CH₃ or CH₂CH₃; R₄ is CN, CO₂H, CHO, CH₃, CONH₂, CHNH; R₅, R₁₀ are OH; ~~or analogues differing from the corresponding "natural" compound in the oxidation state of one or more of the ketide units (i.e. selection of alternatives from the group: CO, CH(OH), -CH-, and -CH2-)~~, with the proviso that said compounds are not borrelidin **(1)**, 12-desnitrile-12-carboxyl borrelidin **(2)**, 10-desmethyl borrelidin **(3)**, 11-epiborrelidin **(4)** or C14,C15-cis borrelidin analogue **(5)** as shown in Figure



‡; and formula 2 , wherein

R₂, R₃, R₆, R₇, R₈, R₉, or R₁₁ are each independently H, OCH₃, CH₃ or CH₂CH₃; R₄ is CN, CO₂H, CHO, CH₃, CONH₂, CHNH₂; R₅, R₁₀ are OH; ~~or analogues differing from the corresponding natural compound in the oxidation state of one or more of the ketide units,~~ and R₁₂ and R₁₃ are independently H or a C1-C4 alkyl group which may be optionally substituted with OH, F, Cl, SH₂ with the proviso that R₁₂ and R₁₃ are not simultaneously H.

Claims 76-95 (Cancelled)